THERAPY TREATMENTS OF PATIENTS WITH OPERABLE CARCINOMA OF THE RECTUM

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的主要目的是比较术前口服卡培他滨联合放疗（XRT）患者与术前持续静脉输注（CVI） 5-FU卡培他滨联合放疗（XRT）患者与术前持续静脉输注（CVI） 5-FU + XRT患者的局部区域复发率。第二个目标是：1)降低原发肿瘤的分期，2)增加接受括约肌手术的患者数量，3)将遗传模式和特异性组织生物标志物的缺失与反应和预后相关联，4)比较口服卡培他滨和CVI 5-FU在直肠癌术前RT设置中的生活质量。5)检查两种CT治疗方案的毒性和护理负担的差异；6)描述直肠癌手术处理类型对手术治疗后1年生活质量的影响。第三个目标是建立一个带注释的组织库，其中包括治疗前和治疗后手术前获得的样本。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aim of this study is to compare the rate of local-regional relapse in patients receiving preoperative oral capecitabine with radiotherapy (XRT) to that in patients receiving preoperative continuous intravenous infusion (CVI) 5-FU capecitabine with radiotherapy (XRT) to that in patients receiving preoperative continuous intravenous infusion (CVI) 5-FU + XRT. The secondary aims are to: 1) downstage the primary tumor, 2) increase the number of patients undergoing sphincter-saying surgery, 3) correlate genetic patterns and the presence of absence of specific tissue biomarkers with response and prognosis, 4) compare oral capecitabine and CVI 5-FU on QOL in the setting of preoperative RT for rectal cancer, 5) examine the differences in toxicity and burden of care for the two CT treatment regimens and 6) describe the impact of the type of surgical management of rectal cancer on QOL at 1 year after surgical treatment. The tertiary aim is to establish an annotated tissue library with samples being obtained prior to therapy and following therapy, prior to surgery.